{
    "clinical_study": {
        "@rank": "82433", 
        "arm_group": [
            {
                "arm_group_label": "GK530G", 
                "arm_group_type": "Experimental", 
                "description": "Fixed-dose combination gel of Adapalene and Benzoyl Peroxide"
            }, 
            {
                "arm_group_label": "CD0271", 
                "arm_group_type": "Active Comparator", 
                "description": "Adapalene 01% Gel"
            }, 
            {
                "arm_group_label": "CD1579", 
                "arm_group_type": "Active Comparator", 
                "description": "Benzoyl Peroxide 2.5% Gel"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of\n      CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the\n      treatment of acne vulgaris for up to 12 weeks, in the Japanese patients."
        }, 
        "brief_title": "Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.", 
        "condition": "Acne Vulgaris", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women at the age of 12 or older at the Screening visit.\n\n          -  Those with clinical diagnosis of acne vulgaris with  more than 20 noninflammatory\n             lesions (open and closed comedones) and 12 to 100 (inclusive) inflammatory lesions\n             (papules, pustules and nodules) on the face (forehead, both cheeks, nose and chin).\n\n        Exclusion Criteria:\n\n          -  Those with more than two nodular acne lesions or any cysts.\n\n          -  Those with the diagnosis of any acne conglobata, any acne fulminans, any chloracne,\n             or any drug induced acne.\n\n          -  Those who have clinically significant abnormal findings or conditions on skin other\n             than acne such as atopic dermatitis, perioral dermatitis, or rosacea that potentially\n             interfere with study assessments according to Investigator's judgment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "412", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02073448", 
            "org_study_id": "RDT.07.SPR.27123"
        }, 
        "intervention": [
            {
                "arm_group_label": "GK530G", 
                "intervention_name": "GK530G", 
                "intervention_type": "Drug", 
                "other_name": "Fixed-dose combination gel of Adapalene and Benzoyl Peroxide"
            }, 
            {
                "arm_group_label": "CD0271", 
                "intervention_name": "CD0271", 
                "intervention_type": "Drug", 
                "other_name": "Adapalene 0.1% Gel"
            }, 
            {
                "arm_group_label": "CD1579", 
                "intervention_name": "CD1579", 
                "intervention_type": "Drug", 
                "other_name": "Benzoyl Peroxide 2.5% Gel"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Adapalene", 
                "Benzoyl Peroxide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Acne Vulgaris", 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Chitose", 
                        "country": "Japan", 
                        "state": "Hokkaido"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Kitami", 
                        "country": "Japan", 
                        "state": "Hokkaido"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Sapporo", 
                        "country": "Japan", 
                        "state": "Hokkaido"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Yokohama", 
                        "country": "Japan", 
                        "state": "Kanagawa"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Kurashiki", 
                        "country": "Japan", 
                        "state": "Okayama"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Daito", 
                        "country": "Japan", 
                        "state": "Osaka"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Neyagawa", 
                        "country": "Japan", 
                        "state": "Osaka"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Sakai", 
                        "country": "Japan", 
                        "state": "Osaka"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Adachi", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Setagaya", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Kagoshima", 
                        "country": "Japan"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Saitama", 
                        "country": "Japan"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Randomized, Double-blinded, Active-controlled Parallel Group Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.", 
        "overall_contact": {
            "email": "GaldermaKK.ClinDev@galderma.com", 
            "last_name": "Tetsuya Mita", 
            "phone": "+81-3-5937-3850"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percent reduction in total lesion counts", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02073448"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percent of Subjects With Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "up to 12 weeks"
        }, 
        "source": "Galderma R&D", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galderma R&D", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}